Synovial Sarcoma Therapeutics Market
Number of pages: 100 | Report Format: PDF | Published date: 02 March, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market size value in 2022 |
US$ 47.6 million |
|
Revenue forecast in 2031 |
US$ 139.8 million |
|
Growth Rate |
CAGR of 12.7% from 2023 to 2031 |
|
Base year for estimation |
2022 |
|
Forecast Period |
2023-2031 |
|
Historical Year |
2021 |
|
Segments covered |
Therapy, End-user, and Region |
|
Regional scope |
North America, Europe, Asia Pacific, and the Rest of the World (ROW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global synovial sarcoma therapeutics market was valued at US$ 47.6 million in 2022 and is expected to register a revenue CAGR of 12.7% to reach US$ 139.8 million by 2031.
Market Fundamentals
Synovial sarcoma is a rare cancer originating from various soft tissues, including muscles, ligaments, and tendons. It frequently develops in the arm, limb, or foot and near joints like the wrist or ankle. It can also arise in the soft tissues of the abdomen or lungs. Malignant synovioma is another name for synovial sarcoma. A deep-seated lump that may be hypersensitive or painful is the first indication of the problem. The growth of synovial sarcoma is gradual.
Although these tumors can develop in young children, most individuals between the ages of 15 and 40 are susceptible to this type of cancer. Synovial sarcoma makes up 5% to 10% of soft tissue sarcoma. In the U.S., one to two cases of synovial sarcoma is identified for every million individuals annually. Synovial sarcoma can produce various symptoms depending on the location in which the tumor develops. A lump with no discomfort is frequently the first symptom of synovial sarcoma. As it grows, it may produce pain or numbness if it is close to a nerve. The mainstay of treatment for synovial sarcoma is surgery. Other than that, the recent development of immunotherapy alone or in combination is frequently used to treat synovial sarcoma. The target is to eliminate the malignancy along with a margin of healthy tissue. This may occasionally entail amputating a leg or even removing an entire muscle or set of muscles. The doctor might advise a regimen of radiation treatment or chemotherapy in addition to surgery to lessen the likelihood of recurrence.
[7685768]
Market Dynamics
Over the past few decades, there has been an increase in the incidence rate of all cancer types. In addition to contributing to 70% of all cancer mortality globally, Africa, Asia, Central America, and South America also account for more than 60% of all new cancer cases. According to the World Health Organization (WHO), cancer reports 8.3 million deaths annually, and 70% more new cancer cases will be reported over the next 20 years. At the same time, synovial sarcoma is estimated to occur 2.75 times per 100,000 people. The lower limbs are involved in most cases. Eight hundred new instances of this tumor are reported annually in the United States, accounting for 5% to 10% of all soft-tissue sarcomas. The most important risk factors are exposure to certain chemicals, previous cancer treatment, irregular lifestyle, along with consuming alcohol, tobacco etc. Therefore, the high prevalence of cancers is the major driving factor for the global synovial sarcoma therapeutics market.
Strong emphasis on research and development to improve the range of treatment options, including monoclonal antibodies and targeted therapies, enhances the growth of the global synovial sarcoma therapeutics market. Although, no targeted treatment is available yet for the treatment of synovial sarcoma. Additionally, a robust and encouraging clinical pipeline is expected to drive the market in the near future. Several therapeutics are in the pipeline for the treatment of synovial sarcoma, some of which are currently undergoing phase III clinical trials. Additionally, promising outcomes are being seen with cutting-edge technologies like ZVex and GLASS, RESOLYSIN, and tumor-specific cytotoxic T-cell therapy. Therefore, a substantial drug pipeline and rising consumer knowledge are the main factors propelling the market's growth. As a result of the increasing demand for pioneering treatment modalities among patients with multiple cancers, the endowment for cancer research has increased over the past few years. The National Institutes of Health (NIH) increased its funding for studies based on cancer treatment by more than 5% year over year in 2018, achieving its highest level. Growing demand for non-conventional treatment choices is the primary factor driving the market's expansion. By speeding up the healing process for patients compared to standard care, increased demand for regenerative medicine enables patients to resume normal activities as soon as feasible. Increased demand for personalized medicine is another significant factor driving the global synovial sarcoma therapeutics market.
However, the side effects associated with synovial sarcoma treatment and the high cost of treatment are the major restraining factors for the global synovial sarcoma therapeutics market. For instance, research carried out in December 2022 at Cuautitlán Izcalli estimated the total medical cost of illness of synovial sarcoma at the National Institute of Cancerology (Mexico City) in the last 10 years (2010-2021) was an average US$ 2823. Also, stringent government regulations, and the high failure in clinical trials, might hamper the market's growth in the future. For example, in November 2018, the clinical phase III trial by Immune Design Corp. to assess if the CMB305 vaccine regimen may help the body's immune system slow or stop synovial sarcoma growth tumor and improve survival was terminated because of not meeting the efficacy level.
Market Ecosystem
The global synovial sarcoma therapeutics market is analyzed from three perspectives: Therapy, End-user, and Region.
Synovial Sarcoma Therapeutics Market by Therapy
[856756]
Based on the therapies, the global synovial sarcoma therapeutics market is segmented as anti-angiogenesis drugs and chemotherapy.
The anti-angiogenesis drugs segment accounted for the largest revenue share of the global synovial sarcoma therapeutics market in 2022. Anti-angiogenesis drugs, also known as angiogenesis inhibitors, are unique cancer-fighting substances because they prevent the development of blood vessels that promote tumor growth rather than the growth of tumor cells. Some frequently used, U.S. Food and Drug Administration (FDA) approved anti-angiogenesis drugs are olaratumab, pazopanib, imatinib, sunitinib, sorafenib, regorafenib for the treatment of soft tissue sarcoma including synovial sarcoma. Anti-angiogenesis drugs have gained considerable attention and are currently one of the most effective methods to treat cancer, owing to the higher efficacy and survival benefit. Tyrosine kinase inhibitors are the most significant category of anti-angiogenesis drugs. Tyrosine kinase inhibitors have fewer or different adverse effects than cytotoxic chemotherapeutic drugs, appear to stabilize tumor progression in a variety of tumor types, and are frequently synergistic with radiotherapy or chemotherapy. Therefore, anti-angiogenesis drugs are administered as a first-line treatment for treating synovial sarcoma.
On the other hand, the chemotherapy segment is also anticipated to account for a sizable revenue share of the global synovial sarcoma therapeutics market. The first-line treatment for synovial sarcoma can be either single-agent or combined chemotherapy. Anthracycline antibiotic doxorubicin is frequently regarded as the most effective single agent generating objective responses in sizable clinical trial settings. First-line chemotherapy for managing synovial sarcoma continues to be primarily based on doxorubicin, either with or without ifosfamide. However, data from new studies indicate that patients with synovial sarcoma may benefit more from ifosfamide and doxorubicin combination therapy than from doxorubicin monotherapy.
With encouraging results, immunotherapy is an emerging treatment for various cancer types. According to studies conducted at the cellular level, some sarcoma subtypes have a comparatively high immunogenicity. Therefore, immunotherapy is rapidly increasing to effectively treat rare soft tissue sarcomas such as synovial sarcoma.
Synovial Sarcoma Therapeutics Market by End-user
Based on the end-users, the global synovial sarcoma therapeutics market is segmented into hospitals, specialty clinics, oncology centers, and others.
The hospitals segment accounted for the largest revenue share of the global synovial sarcoma therapeutics market in 2022. The market has taken the lead as hospitals have more financial assistance to invest in advanced innovative care. Hospitals are the best option for treatment because they have the required medications to offer patients comprehensive care. The rising prevalence of cancers, expanding access to healthcare reimbursements in many developed countries, and ongoing industrial advancements in regenerative therapeutics are the major drivers responsible for segment growth. Multispecialty hospitals may be helpful in the situation of treating multiple ailments simultaneously. The presence of a group of physicians, surgeons, and other experts on staff makes the treatment procedure easier. Additionally, sufficient funds enable the hospitals to have advanced newly launched treatment options and cost-effective diagnostics. As a result, irrespective of income, patients can easily rely on hospitals for treatments.
Synovial Sarcoma Market by Region
Based on the region, the global synovial sarcoma therapeutics market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
North America accounted for the largest revenue share of the global synovial sarcoma therapeutics market in 2022. The high prevalence of soft tissue sarcoma and synovial sarcoma in North America is the major driving factor for the market growth in this region. The American Cancer Society estimated that in 2023, there will be about 13,400 new cases of soft tissue sarcomas diagnosed in the country (7,400 in men and 6,000 in women) and that there will be about 5,140 deaths from soft tissue sarcomas, including synovial sarcoma, affecting 2,720 men and 2,420 women. Moreover, the development of invasive treatments, current FDA approval, and increasing patient and physician adoption of novel approaches are the main factors that have fueled North America's synovial sarcoma therapeutics market growth. Another important reason for expanding the North American synovial sarcoma market is the development of novel therapies and treatments for the disease, owing to funding from the Sarcoma Foundation of America and Synovial Sarcoma Research Foundation. It is anticipated that the populace in developed nations will have more patients as the number of elderly and obese patients rises.
Furthermore, the synovial sarcoma market in Europe is also growing owing to the increased incidence of synovial sarcoma and increased research and development activities for cancer treatment.
Competitive Landscape
The global market for synovial sarcoma therapeutics is relatively competitive with product launches, mergers, and acquisitions. One of the key development strategies that many businesses emphasize is the introduction of new therapeutics, such as immunotherapy, getting those products approved, and engaging in other activities like events and patents. The market defined acquisition, partnership, and collaboration as inorganic development tactics. Given the increasing global market demand for synovial sarcoma therapeutics, these actions have increased the likelihood of having lucrative growth prospects in the future.
Some of the prominent market players are:
Strategic Development
Synovial sarcoma is a rare cancer that can originate from various soft tissues, including muscles, ligaments, and tendons. Anti-angiogenesis drugs, immunotherapy, chemotherapy alone or in combination are utilized to treat synovial sarcoma.
Increased incidence of synovial sarcoma and developed research on oncology are key trends governing the global synovial sarcoma therapeutics market.
Key companies operating the global synovial sarcoma therapeutics market are, Hoffmann-La Roche Ltd., Bayer AG, Eisai Pharmaceuticals Pvt Ltd., Eli Lilly and Company, Cue Biopharma, Adaptimmune Therapeutics Plc, Advenchen Laboratories LLC and other notable companies.
High cost and post-treatment adversities are the main restraining factors for the global synovial sarcoma therapeutics market.
The global synovial sarcoma therapeutics market is expected to grow at a revenue CAGR of 12.7% during the forecast period from 2023 to 2031.
*Insights on financial performance are subject to the availability of information in the public domain
Using the fundamental research and knowledge services capabilities of GRG Health, Growth Plus Reports may now be tailored based on client needs.
GRG Health's unique GrowthMIX strategy and comprehensive research methodology enable us to provide unique and valuable insights to our clients while uncovering trends that would not be discovered using traditional techniques.
Snehal Deshmukh
Principle Consultant
Speak to analyst